Home >  News >  Industry >  Pharma News >  Powered by innovative...

Powered by innovative drugs, pharma industry can be worth USD 200 billion by 2030: Biocon Chief

Mazumdar-Shaw also sought that the government ought to decouple private sector investment and ensure that academic research institutes are funded out of the National Research Foundation.;

Written By :  Ruchika Sharma
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2024-01-25 06:47 GMT   |   Update On 2024-03-26 09:31 GMT
Advertisement

New Delhi: Research-based incentives to develop innovative drugs can help the domestic pharmaceutical sector to be worth USD 200 billion by 2030, Biocon Executive Chairperson Kiran Mazumdar-Shaw said on Wednesday. Terming the pharmaceutical sector as a great contributor in the country's economic growth, she noted that the industry has even greater potential to grow in the years to come.

"India's pharma industry size is estimated at about USD 65 billion today. And by 2030, it is expected to increase to USD 165 billion. Now, I believe it has a potential to even be greater and touch USD 200 billion by 2030," Mazumdar-Shaw told PTI.
Advertisement
But such a level of growth cannot just be driven by generics and biosimilars, it has to involve drug innovation, she noted.
"We have time to develop new drugs which could be blockbusters and I think what is required are research incentives to drive this kind of growth," Mazumdar-Shaw stated.
The government has already come out with various research-linked incentive schemes, but they need to be in much greater strength to drive such growth, she stated.
Mazumdar-Shaw also sought that the government ought to decouple private sector investment and ensure that academic research institutes are funded out of the National Research Foundation.
"I also believe that India Inc. is in a digital transformation journey..I think it will be nice to see some incentives being announced for digital transformation investing something like weighted average tax deduction, that could spur greater investment in this area," she added.
Elaborating further, Mazumdar-Shaw stated that the number of areas in terms of GST should be harmonised with an aim to give certain emerging areas a reprieve when it comes to the taxation.
"I, for one, believe that healthcare is one area where GST I feel is high, because ultimately patients pay for their services. And I think we need to reduce the cost of health care in any case," she noted.
Mazumdar-Shaw sought GST exemption on various essential life saving drugs.
"Why should cancer patients have to pay high GST for very expensive cancer treatments and cancer drugs? I think these are things that the government does need to look into, very prudently," she stated.
Asked to comment on the upcoming elections and its impact on the industry, she emphasised on the need for utilising the GST collections for building the Indian economy.
"What really encourages me about the Indian economy is that our ability to collect more from GST has allowed us actually to be cash surplus...Government is flushed with cash, which I think is a very good side. So we need to ensure that we utilise the GST collections for building the Indian economy in the way it's been done at the moment," she noted.
Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News

Jubilant Ingrevia appoints Sonia Dharap as Vice President - Sales, Business Development (US)

EMA warns of sharp rise in illegal medicines sold in EU

Indegene opens new center in Pune, boosts India presence

Indian medical devices share increased from 10% to 30% of domestic requirements in last 5 years: DoP Secretary

AstraZeneca announces Rs 176 crore investments in India to expand Chennai GITC

Eli Lilly gets USFDA Breakthrough Therapy designation for olomorasib with Keytruda for lung cancer

NPPA fixes Special Ceiling Price for Gufic's Meropenem Dual Chamber Bags

Sun Pharma Fails to Secure CDSCO Nod for BE, Phase III Waiver on Sitagliptin, Glimepiride, Metformin FDC